SAN ANTONIO (EGMN) - The 21-gene recurrence score assay called Oncotype DX can predict risk of recurrence in postmenopausal women with node-positive, estrogen receptor-positive breast cancers, investigators reported December 13 at the annual San Antonio Breast Cancer Symposium.The assay also may be able to define which of these women will not benefit from anthracycline-based adjuvant treatments, said study investigator Dr. Kathy S. Albain, a professor of hematology and oncology at Loyola University,...